To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

Fabry Disease Clinical Trial

— BCLEAR1  

Official title:

A Randomized, Open-label, Active Comparator, 2-arm, Prospective Study to Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04143958
• Other study ID #: LPS15918
• Secondary ID: 2019-000064-21U1
• Status: Withdrawn
• Phase: Phase 4
• Start date: September 2020
• Est. completion date: November 2023

Study information

• Verified date: April 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To assess reduction of plasma lyso-GL3 level after switch to agalsidase beta from agalsidase alfa

Secondary Objectives:

• To assess reduction of kidney podocyte GL3 content after switch to agalsidase beta from agalsidase alfa

• To assess reduction of GL3 content in endothelial skin cells after switch to agalsidase beta from agalsidase alfa

• To assess change in renal function after switch to agalsidase beta from agalsidase alfa

• To assess disease severity and clinical changes after switch to agalsidase beta from agalsidase alfa

• To assess improvement in symptoms of Fabry disease after switch to agalsidase beta from agalsidase alfa

Description:

The study will have a screening period of up to 9 weeks. Eligible participants will be randomized to switch to agalsidase beta or to continue agalsidase alfa in a 1:1 ratio for a period of 12 months (52 weeks).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2023
• Est. primary completion date: November 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 16 Years to 45 Years

Eligibility

Inclusion criteria :

• Male participant must be 16 to 45 years of age inclusive, at the time of signing the informed consent.

• Participants who are diagnosed with classic Fabry disease based on phenotype, presence or absence of characteristic Fabry disease symptoms including neuropathic pain, clustered angiokeratoma and/or cornea verticillata, leucocyte a-GAL A enzyme activity (3% or less compared to control), and genotype (optional).

• Participants who are currently receiving agalsidase alfa for a minimum of 6 months at an average dose of 0.2 mg/kg every other week (ie, every 2 weeks) at baseline.

• Participants who are naïve to agalsidase beta.

• Participants with estimated glomerular filtration rate (eGFR) =60 mL/min/1.73 m^2 at screening and baseline.

• Proteinuria level as measured by 2 separate, morning, clean-catch urine samples taken a few days apart demonstrating an averaged urine protein-creatinine ratio of <0.5 (ie, <500 mg protein per 1 g creatinine) between the 2 samples. For participants on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), the criterion is to be met both prior and after a temporary interruption of ACEIs/ARBs for 4 weeks.

• Participants with plasma lyso-GL3 levels >20 ng/mL on 2 consecutive samples taken at least 4 weeks apart.

• Participant's medical records (including eGFR values) available and accessible during the study period.

• Participant and/or participant's legal representative has given signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. For potential participants age 16 to 18 years, a parent or legal representative is required to sign the ICF, and the potential participant is also required to sign an informed assent form.

Exclusion criteria:

• Participants with severe renal impairment (end-stage renal disease, dialysis, or renal transplantation) and/or nephropathies (including diabetic).

• Participants with rapid renal decline: Loss of >6mL/min/1.73 m^2 at screening compared to the most recent eGFR value approximately 12 months prior to screening.

• Participants with advanced cardiac failure (Stage D).

• Participants with bleeding disorder, prior history of unexplained bleeding episodes, or receiving mandatory anticoagulants or antiplatelets for any indication not allowing interruption of therapy for renal biopsy.

• Participants with diagnosed diabetes.

• Participants with history of anaphylaxis to Enzyme Replacement Therapy (ERT).

• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

• Participants treated for more than 5 years with agalsidase alfa at an average dose of 0.2 mg/kg every other week (ie, every 2 weeks) prior to randomization.

• Exposure to migalastat or any investigational study intervention, except agalsidase alfa, for Fabry disease in the last 5 years prior to study participation. Patients who previously participated in any agalsidase alfa clinical study will be eligible if they meet other criteria.

• Exposure to any investigational drugs in the last 4 weeks or 5 half-lives, whichever is longer, prior to screening visit or concomitant enrollment in any other clinical study involving an investigational study treatment.

• Individuals accommodated in an institution because of regulatory or legal order; prisoners or subjects who are legally institutionalized.

• Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

• Participants are dependent on the Sponsor or Investigator or deemed vulnerable for any reason (in conjunction with Section 1.61 of the International Council for Harmonisation Good Clinical Practice [ICH-GCP] Ordinance E6).

• Participants who are employees of the clinical study center or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.

• Any specific situation during study implementation/course that may raise ethics consideration

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Fabry Disease

Intervention

Drug:
• agalsidase beta (GZ419828)
Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
• agalsidase alfa
Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Plasma globotriaosylsphingosine (lyso-GL3) level	Change from baseline to 12 months (week 52) for plasma lyso-GL3 level	Baseline, 12 months (week 52)
Secondary	Change in GL3 content in podocytes	Change from baseline to 12 months (week 52) for GL3 content in podocytes	Baseline, 12 months (week 52)
Secondary	Change in GL3 content in endothelial skin cells	Change from baseline to 12 months (Week 52) for GL3 content in endothelial skin cells	Baseline, 12 months (week 52)
Secondary	Change in measured glomerular filtration rate (mGFR)	Change from baseline to 12 months (Week 52) for measured glomerular filtration rate (mGFR) (measured by iohexol clearance)	Baseline, 12 months (week 52)
Secondary	Change in estimated glomerular filtration rate (eGFR) calculated	Change from baseline to 12 months (Week 52) for estimated glomerular filtration rate (eGFR) calculated using age appropriate formula [Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)/ Bedside-Schwartz]	Baseline, 12 months (week 52)
Secondary	Change in Mainz Severity Score Index (MSSI) total score	Change from baseline to 12 months (Week 52) for Mainz Severity Score Index (MSSI), based on MSSI total score	Baseline, 12 months (week 52)
Secondary	Change in Fabry Disease Patient Reported Outcomes (FD-PRO) total symptom score	Change from baseline to 12 months (Week 52) in Fabry Disease Patient Reported Outcomes (FD-PRO) score, based on FD-PRO total symptom score	Baseline, 12 months (week 52)